Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.44 |
| ▸ | PLA2G2E | Q9NZK7 | 4/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.44 |
| ▸ | PLA2G2F | Q9BZM2 | 3/20 | 0.44 |
| ▸ | PLA2G2D | Q9UNK4 | 3/20 | 0.44 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.42 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.42 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6129642 | 0.88 | PLA2G2A (0.41) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL7675913 | 0.87 | ADRA1D (0.40) | PLA2G2A | |
| SCHEMBL6129590 | 0.87 | PLA2G2A (0.40) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL27844984 | 0.87 | PLA2G2A (0.49) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL6129648 | 0.87 | PLA2G2A (0.46) | PLA2G2APLA2G10 | |
| SCHEMBL6129602 | 0.87 | PLA2G2A (0.41) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL6129635 | 0.86 | PLA2G2A (0.39) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL6129617 | 0.86 | PLA2G2A (0.43) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL27497627 | 0.86 | PLA2G2A (0.46) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 | |
| SCHEMBL6129601 | 0.85 | PLA2G2A (0.39) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | claimed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | claimed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | claimed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-4045026-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | Ophirex, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076712-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | OPHIREX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G10 9/4885PLA2G2E 14/4885 |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G10 8/4885PLA2G2E 13/4885 |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 14/4885PLA2G10 7/4885PLA2G2E 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.